Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Herve Avet-Loiseau, Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Jill Corre, Laurent Garderet, Lionel Karlin, Jérôme Lambert, Margaret Macro, Aurore Perrot, Pieter Sonneveld, Mark-David Levin, Saskia Klein, Christopher Chiu, Lixia Pei, Carla De Boer, Tobias Kampfenkel, Soraya Wuilleme, Marie-Christine Béné, on behalf of IFM and HOVON
Institutions: Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-Louis, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Pitié-Salpêtrière Hospital, Centre de Recherche Saint-Antoine, Hospices Civils de Lyon, Hôpital Lyon Sud, Centre Hospitalier Universitaire de Caen Normandie, Erasmus MC Cancer Institute, Albert Schweitzer Ziekenhuis, Meander Medisch Centrum, Janssen Research & Development (United States), Janssen (Netherlands)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2957663505